Evidence map›Paper›PMID 30992057›Full record

ArticleBMC research notes2019

Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.

Mark Reglinski, Shiranee Sriskandan

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mark ReglinskiFaculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.
Shiranee SriskandanFaculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. s.sriskandan@imperial.ac.uk.ORCID http://orcid.org/0000-0002-5214-4941
Hammersmith Hospital · GB

Funding

Medical Research Council Confidence in ConceptMedical Research Council G0800777Medical Research Council MC_PC_12015National Institute for Health Research HPRU-2012-10047United Kingdom Clinical Research Collaboration G0800777
6 · The paper itself

Abstract

objectiveIntravenous immune globulin (IVIG), pooled from human blood, is a polyspecific antibody preparation that inhibits the super-antigenic proteins associated with streptococcal and staphylococcal toxic shock, and the Shiga toxin. In addition to this toxin-neutralising activity, IVIG contains other pathogen-reactive antibodies that may confer additional therapeutic benefits. We sought to determine if pathogen-reactive antibodies that promote opsonophagocytosis of different organisms can be sequentially affinity-purified from one IVIG preparation.

resultsAntibodies that recognise cell wall antigens of Streptococcus pyogenes, Staphylococcus aureus, and vancomycin-resistant enterococcus (VRE) were sequentially affinity-purified from a single preparation of commercial IVIG and opsonophagocytic activity was assessed using a flow cytometry assay of neutrophil uptake. Non-specific IgG-binding proteins were removed from the S. aureus preparations using an immobilised Fc fragment column, produced using IVIG cleaved with the Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS). Affinity-purified anti-S. aureus and anti-VRE immunoglobulin promoted significantly higher levels of opsonophagocytic uptake by human neutrophils than IVIG when identical total antibody concentrations were compared, confirming activity previously shown for affinity-purified anti-S. pyogenes immunoglobulin. The opsonophagocytic activities of anti-S. pyogenes, anti-S. aureus, and anti-VRE antibodies that were sequentially purified from a single IVIG preparation were undiminished compared to antibodies purified from previously unused IVIG.

Indexed as

Antibodies, BacterialAntigens, BacterialCell WallChromatography, AffinityHumansImmunoglobulin Fc FragmentsImmunoglobulins, IntravenousNeutrophilsOpsonin ProteinsPhagocytosisPrimary Cell CultureStaphylococcus aureusStreptococcus pyogenesVancomycin-Resistant EnterococciAntibodies, BacterialAntigens, BacterialImmunoglobulin Fc FragmentsImmunoglobulins, IntravenousOpsonin ProteinsAntimicrobial resistanceEnterococcusIVIGOpsonophagocytic killingPooled human immunoglobulinStaphylococcus aureus

Identifiers

PMID30992057
PMCPMC6466806
OpenAlexW2945612861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.